Effects of oral bovine lactoferrin on a mouse model of inflammation associated colon cancer
Effects of oral bovine lactoferrin on a mouse model of inflammation associated colon cancer
复制标题
DOI：
10.1139/bcb-2020-0087
复制
发表时间：
2021-02-01
影响因子：
2.9
通讯作者：
Tsuda, Hiroyuki
中科院分区：
文献类型：
--
作者：
Tanaka, Hajime;Gunasekaran, Sivagami;Tsuda, Hiroyuki
患有溃疡性结肠炎或结肠克罗恩病的患者患结直肠癌的风险显著增加。据报道，牛乳铁蛋白（bLF）抑制大鼠和小鼠结肠癌的发展，在安慰剂对照试验中，摄入bLF抑制肠息肉的生长。此外，在一项病例研究中，据报告，一名克罗恩病患者在每天摄入1 g bLF的同时，病情缓解持续了7年以上。因此，bLF对结肠癌的发生具有抑制作用，并且它还可以促进克罗恩病的缓解。本研究的目的是研究bLF在与肠易激性疾病（IBD）相关的结肠直肠癌小鼠模型中的作用。将小鼠分成4组：（i）不处理;（ii）仅用bLF处理;（iii）用氧化偶氮甲烷加葡聚糖硫酸钠（AOM + DSS）处理;和（iv）用AOM + DSS + bLF处理。AOM用于引发肠癌，DSS用于诱导C57 BL/6小鼠肠道中的IBD样炎症。在研究结束时，用AOM + DSS + bLF处理的小鼠具有比用AOM + DSS而没有bLF处理的小鼠更好的粪便评分、更少的结肠病变和更少的体重减轻。然而，两组之间在肿瘤负荷方面没有统计学显著差异。
Patients with ulcerative colitis or colonic Crohn's disease have a significantly increased risk of developing colorectal cancer. Bovine lactoferrin (bLF) reportedly inhibited the development of colon cancer in rats and mice, and in a placebo controlled trial, ingestion of bLF inhibited the growth of intestinal polyps. In addition, in a case study, a patient with Crohn's disease was reported to have remained in remission for over 7 years while ingesting 1 g of bLF daily. Thus, bLF has an inhibitory effect on colon carcinogenesis, and it may also promote remission of Crohn's disease. The purpose of this study was to investigate the effects of bLF in a mouse model of colorectal cancer related to irritable bowel disease (IBD). The mice were divided into 4 groups: (i) no treatment; (ii) treated with bLF only; (iii) treated with azoxymethane plus dextran sulfate sodium (AOM + DSS); and (iv) treated with AOM + DSS + bLF. AOM was used to initiate intestinal cancer, and DSS was used to induce IBD-like inflammation in the intestine of the C57BL/6 mice. At the end of the study, the mice treated with AOM + DSS + bLF had a better fecal score, fewer lesions in the colon, and less weight loss than the mice treated with AOM + DSS without bLF. However, there were no statistically significant differences between the two groups with respect to tumor burden.